Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOWLNASDAQ:INABNASDAQ:KLRSNASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOWLWerewolf Therapeutics$1.23-3.9%$0.93$0.60▼$4.73$57.44M0.48429,962 shs378,012 shsINABIN8bio$0.15-3.9%$0.16$0.11▼$1.74$13.45M0.232.35 million shs49.65 million shsKLRSAllovir$2.92-1.4%$0.00$2.64▼$24.15$54.61M0.737,788 shs16,200 shsSTTKShattuck Labs$1.02-5.6%$0.95$0.69▼$7.53$48.86M1.74359,069 shs71,278 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOWLWerewolf Therapeutics0.00%+6.96%+41.23%-0.81%-75.83%INABIN8bio0.00%+1.73%-13.24%-45.22%-85.69%KLRSAllovir0.00%+291,999,900.00%+291,999,900.00%+291,999,900.00%+291,999,900.00%STTKShattuck Labs0.00%-5.56%-5.56%-22.73%-85.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOWLWerewolf Therapeutics3.132 of 5 stars3.51.00.00.03.35.00.6INABIN8bio3.2668 of 5 stars3.53.00.00.03.02.51.3KLRSAllovirN/AN/AN/AN/AN/AN/AN/AN/ASTTKShattuck Labs2.5757 of 5 stars3.42.00.00.02.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOWLWerewolf Therapeutics 3.00Buy$8.33577.51% UpsideINABIN8bio 3.00Buy$6.003,970.56% UpsideKLRSAllovir 0.00N/AN/AN/ASTTKShattuck Labs 2.71Moderate Buy$7.50635.29% UpsideCurrent Analyst Ratings BreakdownLatest INAB, KLRS, STTK, and HOWL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.003/27/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/27/2025STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/17/2025STTKShattuck LabsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/17/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$4.003/14/2025INABIN8bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $6.003/12/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/12/2025HOWLWerewolf TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOWLWerewolf Therapeutics$1.14M48.29N/AN/A$3.08 per share0.40INABIN8bioN/AN/AN/AN/A$0.58 per shareN/AKLRSAllovirN/AN/AN/AN/AN/AN/ASTTKShattuck Labs$4.61M10.61N/AN/A$3.41 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOWLWerewolf Therapeutics-$37.37M-$1.67N/AN/AN/A-578.80%-58.83%-38.45%8/14/2025 (Estimated)INABIN8bio-$30.01M-$0.45N/AN/AN/AN/A-197.15%-130.48%8/14/2025 (Estimated)KLRSAllovirN/AN/A0.00∞N/AN/AN/AN/AN/ASTTKShattuck Labs-$87.30M-$1.39N/AN/AN/A-1,156.46%-61.92%-54.49%8/7/2025 (Estimated)Latest INAB, KLRS, STTK, and HOWL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A5/8/2025Q1 2025INABIN8bio-$0.06-$0.07-$0.01-$0.07N/AN/A5/1/2025Q1 2025STTKShattuck Labs-$0.29-$0.27+$0.02-$0.27N/AN/A3/27/2025Q4 2024STTKShattuck Labs-$0.38-$0.37+$0.01-$0.37$1.00 millionN/A3/13/2025Q4 2024INABIN8bio-$0.07-$0.04+$0.03-$0.04N/AN/A3/11/2025Q4 2024HOWLWerewolf Therapeutics-$0.43-$0.46-$0.03-$0.46$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/AKLRSAllovirN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOWLWerewolf Therapeutics0.2910.1010.10INABIN8bio0.051.841.84KLRSAllovirN/AN/AN/ASTTKShattuck LabsN/A7.967.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOWLWerewolf Therapeutics64.84%INABIN8bio92.05%KLRSAllovir66.05%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipHOWLWerewolf Therapeutics21.10%INABIN8bio15.50%KLRSAllovir32.07%STTKShattuck Labs10.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOWLWerewolf Therapeutics4044.87 million35.16 millionOptionableINABIN8bio2090.77 million61.25 millionNot OptionableKLRSAllovir11018.70 millionN/AN/ASTTKShattuck Labs10047.90 million42.73 millionOptionableINAB, KLRS, STTK, and HOWL HeadlinesRecent News About These CompaniesShattuck Labs Advances SL-325 Program Amid Financial ProgressMay 6, 2025 | tipranks.com683 Capital Management LLC Buys New Position in Shattuck Labs, Inc. (NASDAQ:STTK)May 4, 2025 | marketbeat.comShattuck Labs Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 1, 2025 | globenewswire.comShattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comShattuck Labs Full Year 2024 Earnings: Misses ExpectationsMarch 29, 2025 | uk.finance.yahoo.comShattuck Labs reports Q4 EPS (37c), consensus (32c)March 29, 2025 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)March 29, 2025 | markets.businessinsider.comShattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | finanznachrichten.deShattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationMarch 18, 2025 | msn.comShattuck Labs initiated with an Outperform at LeerinkMarch 17, 2025 | markets.businessinsider.comFavourable Signals For Shattuck Labs: Numerous Insiders Acquired StockMarch 11, 2025 | finance.yahoo.comH.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)February 21, 2025 | markets.businessinsider.comShattuck Labs’ SL-325 shows positive results in inflammatory bowel diseaseFebruary 20, 2025 | markets.businessinsider.comShattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 20, 2025 | globenewswire.comShattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in BerlinFebruary 13, 2025 | quiverquant.comShattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 13, 2025 | globenewswire.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | markets.businessinsider.comShattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | quiverquant.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis CongressFebruary 4, 2025 | globenewswire.comShattuck Labs, Inc. to Present Corporate Update at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookPfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?3 Underrated Stocks Quietly Delivering Big GainsBy Thomas Hughes | May 13, 2025View 3 Underrated Stocks Quietly Delivering Big GainsDisney Stock Jumps on Earnings—Is the Magic Sustainable?By Chris Markoch | May 7, 2025View Disney Stock Jumps on Earnings—Is the Magic Sustainable?INAB, KLRS, STTK, and HOWL Company DescriptionsWerewolf Therapeutics NASDAQ:HOWL$1.23 -0.05 (-3.91%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.19 -0.04 (-3.25%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.IN8bio NASDAQ:INAB$0.15 -0.01 (-3.91%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.13 -0.01 (-9.77%) As of 05/30/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Allovir NASDAQ:KLRS$2.92 -0.04 (-1.35%) As of 05/30/2025 04:00 PM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Shattuck Labs NASDAQ:STTK$1.02 -0.06 (-5.56%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.01 -0.01 (-1.37%) As of 05/30/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
